EVERSANA, Prosoma Partner Up on Therapeutic Commercialization
Digital therapy will help support mental health of cancer patients
EVERSANA is collaborating with Prosoma Digital Therapeutics, a digital therapeutics oncology company, in which the global services provider will assist with the anticipated launch and commercialization for Prosoma’s digital therapy to support the mental health of cancer patients.
The digital therapy, Living Well, is the company’s branded application that is designed to improve the quality of life and reduce stress, anxiety, and depression symptoms related to cancer diagnosis and treatment.
“As we looked to navigate the complexity of commercializing our digital solutions in the United States, it became clear we need[ed] a partner with the infrastructure and experience to help us move quickly,” says Andrzej Jonczyk, CEO, Prosoma US. “…[EVERSANA’s] integrated platform and deep experience in digital therapeutics make them the perfect partner to help bring our important therapies to patients.”
An EVERSANA spokesperson also confirmed that the company will be working with Prosoma toward appropriate approvals with governing bodies, including the FDA, to bring Living Well to cancer patients. As a part EVERSANA’s commercialization services, it will partner with Prosoma on a comprehensive payer reimbursement strategy.
Newsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
Study Connects COVID-19 Treatment Disparities to Gaps in Testing and Virtual Access
July 11th 2025New research finds that nearly half of the racial and ethnic disparities in outpatient COVID-19 antiviral prescriptions stem from encounter-level care barriers, such as limited access to rapid tests and telehealth, which emphasizes the need for systemic and practice-level reforms.
